Metastatic Castration-Resistant Prostate Cancer Articles

Treatment Developments Shaking Up Landscape for Nonmetastatic CRPC
Mark J. Mann, MD, discusses the developing treatment landscape for patients with nonmetastatic CRPC.
FDA Grants Enzalutamide Priority Review for Nonmetastatic CRPC
The FDA has granted a priority review to a supplemental new drug application (sNDA) for enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.
CTCs Demonstrate Predictive Power in Prostate Cancer
Investigators looking for a superior means of testing for response to therapy in metastatic castration-resistant prostate cancer said they found the solution in a study of circulating tumor cells.
An analysis of results from 5 clinical trials showed that circulating tumor cell (CTC) conversion and CTC value ≥ 1 at baseline were superior predictors of overall survival than PSA in men with metastatic castration-resistant prostate cancer.
Bipolar Androgen Therapy Effective After Enzalutamide in mCRPC
One-third of asymptomatic men with metastatic castration-resistant prostate cancer who progressed on enzalutamide (Xtandi) achieved a 50% decline in PSA concentration from baseline (PSA50) following bipolar androgen therapy.
Second-Line Docetaxel Superior to ARATA in mCRPC
Men with metastatic castration-resistant prostate cancer who progressed following initial treatment with an androgen receptor-axis-targeted agent had better survival when treated with docetaxel in second-line.
Role of PARP Inhibitors Developing in mCRPC
Alicia Morgan, MD, discusses the role of PARP inhibitors as a novel treatment strategy for patients with metastatic castration-resistant prostate cancer.
Immunotherapy Continues Growth With Trials in mCRPC
Julie Graff, MD, comments on the state of immunotherapy in mCRPC and some ongoing research in the field.
Radium-223 Well Tolerated in Long-Term Safety Results in mCRPC
Three-year safety results from the ALSYMPCA trial showed that treatment with radium-223 dichloride (Xofigo) for men with mCRPC and symptomatic bone metastases was associated with minimal nonhematologic AEs.
Radium-223/Abiraterone Phase III mCRPC Trial Unblinded
The phase III ERA223 trial exploring radium-223 dichloride plus abiraterone acetate in patients with asymptomatic or mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer has been unblinded early.
Publication Bottom Border
Border Publication